𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Different dose regimens of 5-fluorouracil and interferon-α in patients with metastatic colorectal carcinoma

✍ Scribed by P. Ragnhammar; H. Blomgren; D. Edler; G. Lundell; I. Magnusson; T. Sonnenfeld


Book ID
116166170
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
688 KB
Volume
31
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Comparison of 5-fluorouracil with 5-fluo
✍ Frederick Richards II; Thomas L. Pajak; Miles R. Cooper; Charles L. Spurr 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

Thirty-eight patients with metastatic colorecal carcinoma were treated with 5-fluorouracil (5-FU), and 38 patients were treated with the combination of 5-FU, cyclophosphamide, and methotrexate. In terms of percent response, response duration, and survival there was no apparent difference between the

A comprehensive review of 5-fluorouracil
✍ David Machover 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Background: Colorectal carcinoma is the third leading cause of cancer-related death. the primary treatment for patients with metastatic colorectal carcinoma is systemic chemotherapy with 5-fluorouracil (5-fu) and leucovorin (lv), a biomodulator of 5-fu that has been shown to enhance its activity

Bimonthly high dose leucovorin and 5-flu
✍ Christophe Tournigand; Christophe Louvet; Aimery de Gramont; Elisabeth Lucchi; J 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

disease progression. IFN was administered subcutaneously three times weekly at for the Groupe d'Etude et de a dose of 3 MU (body surface area [BSA] õ 1.75 m 2 ) or 4.5 MU (BSA ¢ 1.75 m 2 ). Recherche sur les Cancers de RESULTS. World Health Organization toxicity Grade 3-4 occurred in 21 patients l'O